COCP READ THE FULL COCP RESEARCH REPORT Business Update Fast Track Designation for CDI-988 On April 2, 2026, Cocrystal Pharma, Inc. (NASDAQ: COCP) announced that the U.S. Food and Drug Administration ...
Resident doctor strikes are due to continue until next Monday (April 13). NHS Trusts across Surrey have said they aim to keep ...
The FDA grants Fast Track designation to CDI-988, an oral antiviral for the treatment and prophylaxis of norovirus infection in adult patients.
Rotavirus can be dangerous for infants and young children. Here’s what the latest data says about California, Texas and key ...
AI predicted that a forgotten breast cancer drug could be repurposed to treat many respiratory and gastrointestinal viruses, ...
CDI-988 was designed and developed as an inhibitor of a highly conserved region of noroviruses, coronaviruses, and other 3CL viral proteases. A Phase 1b norovirus challenge study is underway at Emory ...
FDA Fast Track designation supports accelerated development and expedites regulatory reviewNorovirus is responsible for an ...
Phase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral ...
A hospital has brought in visiting restrictions on its wards because of an increase in norovirus cases. Surrey & Sussex Healthcare NHS Trust, which runs the East Surrey Hospital i ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results